Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE Our findings suggest that the frequency of HER2 overexpression or amplification was low in Chinese CRC patients, and provide a rationale for further evaluation of HER2 in CRC based on the HERACLES criteria and the HER2 diagnostic criteria for gastroesophageal adenocarcinoma. 31720832

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Sub-protocol Q. 31504139

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression BEFREE Human epidermal growth factor receptor 2 (HER2) is expressed in some gastric and gastroesophageal junction adenocarcinomas. 30624589

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression BEFREE Hepatoid adenocarcinomas showed relatively frequent expressions of HER2 (score 3+/2+: 21%/19%). 30946937

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation BEFREE Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma component. 30825613

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE This review provides up-to-date practical guidance to clinicians on accurate HER2 testing and interpretation of results in gastric/GEJ adenocarcinoma. 30928424

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE For this double-blind, randomised, placebo-controlled, phase 3 trial done at 126 centres in 20 countries, we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate organ function. 30718072

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE Progress and challenges in HER2-positive gastroesophageal adenocarcinoma. 31101074

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE The HER2 concordance rate between primary gastric adenocarcinomas and CB-MEs was 88.9% (40/45) (κ = - 0.056). 31477048

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE Although several molecular classifications have been proposed, precision medicine for HER2-amplified GEA patients still represents a challenge. 31046106

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE We enrolled 26 patients with metastatic HER2-positive gastric or GE junction adenocarcinoma between February 2011 and June 2015. 30088161

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE The most recent brain metastases were HER2+ for 32% of patients: 2 of 3 esophageal squamous cell carcinomas, 3 of 10 esophageal adenocarcinomas (ACs), 3 of 14 colorectal ACs, and 1 of 1 pancreatic AC. 30373904

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE Compared with patients with adenocarcinoma only, those with ASC demonstrated profoundly worse disease-specific survival (5-year event-free rate, 34% vs. 6%; multivariate hazard ratio, 2.87 [95% confidence interval, 1.59-4.76]; P=0.0010) and overall survival (P=0.0027) that was independent of known prognostic factors and HER2 status. 30516569

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE Complete Remission of Metastatic HER2+ Oesophagogastric Junctional Adenocarcinoma under long-term Trastuzumab Treatment. 31826054

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE We found recurrent somatic missense mutations in 22 genes (including PIK3CA, ERBB2, and GNAS) and a widespread APOBEC cytidine deaminase mutagenesis pattern (TCW motif) in both adenocarcinoma (ACC) and squamous cell carcinomas (SCCs). 31624127

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression BEFREE Significance of HER2 protein expression and <i>HER2</i> gene amplification in colorectal adenocarcinomas. 31040898

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE Earlier, we showed that the targeted toxin DARPin-PE40 consisting of the HER2-specific non-immunoglobulin polypeptide (the targeting module) and a fragment of <i>Pseudomonas</i> exotoxin A (the toxic module) exhibits an antitumor effect <i>in vivo</i> against the HER2-positive adenocarcinoma xenograft. 29104782

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation BEFREE Ion AmpliSeq Cancer Panel detected 9 potentially actionable variants in 29 adenocarcinomas that were wild type by the 8-gene panel testing (9 of 29, 31.0%) in the following genes: ERBB2 (3 of 29, 10.3%), STK11 (2 of 29, 6.8%), PTEN (2 of 29, 6.8%), FBXW7 (1 of 29, 3.4%), and BRAF G469A (1 of 29, 3.4%). 29219616

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE Trastuzumab® is used for human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma. 29277796

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression BEFREE Only 2 AVCs (7.7%; both intestinal-type) showed a HER2 overexpression (both 2+), which corresponded to a HER2 gene amplification at CISH analysis. 29731265

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation BEFREE HER2 S310Y single site substitution was discovered in recent years and afatinib efficacy for adenocarcinoma patients harboring S310Y mutation has not been reported. 29561699

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance. 29318901

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE The use of biologics targeted to the human epidermal growth factor receptor 2 (HER2) protein is the latest addition to the armamentarium used to fight advanced gastric or gastro-oesophageal junction adenocarcinoma. 29439009

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE To gain a better understanding of the concordance of IHC and FISH results at our institution, we identified all gastroesophageal adenocarcinomas at our institution tested for HER2 (n=125). 27153447

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE Brain metastasis in gastroesophageal adenocarcinoma and HER2 status. 29429124

2018